Refractory Peripheral T-Cell Lymphoma Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Refractory Peripheral T-Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic127 enrolled2 locationsNCT03017820
Recruiting
Phase 2

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
National Cancer Centre, Singapore24 enrolled1 locationNCT06160843
Recruiting
Phase 2

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma
Great Novel Therapeutics Biotech & Medicals Corporation33 enrolled5 locationsNCT05833724
Recruiting
Phase 1Phase 2

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University33 enrolled1 locationNCT06855823
Recruiting
Phase 1Phase 2

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.95 enrolled1 locationNCT05934513
Recruiting
Phase 1Phase 2

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027